This Patient Alert Card has been developed for prescribers and healthcare professionals (HCPs) involved in the care of patients treated with Cablivi (caplacizumab), to provide further information about the potential serious risks associated with the use of this medicine. For hard copies of this information please contact medical information department on 0800 035 2525 or email [email protected]

Caffeine Citrate 10m/ml Solution for Injection and Oral Solution laminated card

This risk minimisation material is a condition of the marketing authorisation. This Checklist supports the communication of critical tasks and actions throughout the patient’s cycle of treatment with mavacamten; before starting treatment, during treatment, and after treatment has been discontinued.

This risk minimisation material is a condition of the marketing authorisation. It supports the communication of critical safety measures, including notifying your doctor if you experience symptoms of heart failure, not starting or stopping any medications without talking to your doctor, and avoiding pregnancy. Please ensure that you carry this card with you at all times.

This risk minimisation material is a condition of the marketing authorisation. It supports the communication of critical safety measures, including notifying your doctor if you experience symptoms of heart failure, not starting or stopping any medications without talking to your doctor, and avoiding pregnancy. Embryo-fetal toxicity risk information is presented as a tear-out in the Patient Guide, which can be removed if the risk of embryo-fetal toxicity does not apply.

For hard copies, please contact medical information department at 0800 035 2525 or email [email protected].

For hard copies, please contact medical information department at 0800 035 2525 or email [email protected]

For hard copies, please contact medical information department at 0800 035 2525 or email [email protected].

Important information about CASGEVY for patients and carers

Important information for Healthcare Professionals about CASGEVY

Important information for patients regarding CASGEVY

This material is provided by Roche Products Ltd and forms part of the licence requirement. Please ensure that you are familiar with this material as it contains important safety information

This material is provided by Roche Products Ltd as a licence requirement. Please ensure that you are familiar with this material as it contains important safety information.

This guide details the risk of teratogenicity.

This guide details the risks of miscarriage and birth defects.

For hard copies of this information please contact medical information department on 0800 035 2525 or email [email protected]

For hard copies of this information please contact medical information department on 0800 035 2525 or email [email protected]

The objective of this document is to provide guidance to healthcare professionals for the management of patients receiving Cerezyme (imiglucerase) at home. For hard copies of this information please contact medical information department on 0800 035 2525 or email [email protected]

The objective of this document is to provide patients with guidance on how to receive Cerezyme (imiglucerase) at home. It is the responsibility of the treating physician to supply this material to patients only if the treating physician decides that the patient is eligible for home infusion treatment. For hard copies of this information please contact medical information department on 0800 035 2525 or email [email protected]

This short checklist is designed to help you and your pharmacist discuss Cialis Together and decide whether it is right for you. It should be filled in as accurately as possible so that the pharmacist can give you the most appropriate advice and/ or treatment. Please answer all of the questions by ticking the box that applies. The answers are needed to ensure that Cialis Together can be supplied appropriately, as it may not be suitable for you if you are taking certain medications or have certain medical conditions. The pharmacist will discuss the questions and your answers with you so any notes you make will help with this. If the pharmacist supplies Cialis Together to you please read the leaflet carefully.

This Pharmacist Checklist Quick Guide is provided to assist you in your assessment of a patient’s suitability for Cialis Together. It is designed to be used in conjunction with the Cialis Together Checklist. The Cialis Together Checklist can be provided to the patient to complete before consultation with you or it can be used as part of your consultation with the patient. Use of this material is optional and pharmacists should use their professional judgement to decide when and how to use it.

This guide, together with the Cialis Together checklist and Pharmacist Checklist Quick guide (which helps with the interpretation of patients'answers), has been developed by Sanofi to support pharmacists and pharmacy assistants in managing the risks related to Cialis Together and enabling its appropriate supply and use.

After assessing the man, using the Cialis Together Pharmacist Checklist Quick Guide, complete and supply them with either the Repeat Purchase Card or Referral Card by tearing off the appropriate card.

Cibinqo Patient Card

Prescriber brochure to provide guidance on assessments prior to prescribing, management, monitoring and safety considerations related to the Risk Management Plan

Checklist in conjunction with the Summary of Product Characteristics during combined hormonal contraceptive (CHC) consultations.

Important information for women about risk of blood clots with combined hormonal contraceptives (CHC).

Please use this checklist in conjunction with the Summary of Product Characteristics during combined hormonal contraceptive (CHC) consultations. •Thromboembolism (e.g. deep vein thrombosis, pulmonary embolism, heart attack and stroke) is a rare but important risk with use of a CHC.

All women should understand: the small risk of blood clots with combined hormonal contraceptives; what other conditions increase the risk of a blood clot; the signs and symptoms of a blood clot; and when you need to tell a healthcare professional that you are using a combined hormonal contraceptive. Although the risk is small, blood clots can be serious. This information will help you minimise your risk.

IMPORTANT INFORMATION FOR WOMEN ABOUT RISK OF BLOOD CLOTS WITH COMBINED HORMONAL CONTRACEPTIVES

This alert card contains important safety information that patients need to be aware of before they are given CIMZIA and during treatment with CIMZIA.

Cinryze Patient Diary

Cinryze HCP Guide

Cinryze Patient Guide

Please use this checklist in conjunction with the Summary of Product Characteristics during combined hormonal contraceptive (CHC) consultations. Cyproterone acetate and ethinylestradiol tablet are used for the treatment of moderate to severe acne related to androgen-sensitivity (with or without seborrhoea) and/or hirsutism, in women of reproductive age.

The review recommended that all women should understand: the small risk of blood clots with combined hormonal contraceptives; what other conditions increase the risk of a blood clot; the signs and symptoms of a blood clot; and when you need to tell a healthcare professional that you are using a combined hormonal contraceptive. Although the risk is small, blood clots can be serious. This information will help you minimise your risk.

Risk of blood clots with combined hormonal contraceptives. All combined contraceptives increase the rare but important risk of having a blood clot. It is important to recognise the signs and symptoms to look out for and what action to take.

Patient Card with QRD Code - To access the instructional video, please scan the QR code with a smartphone/device.

Colobreathe® Healthcare Professional and Patient Guide with Instructions for Use

This material is provided by Roche Products Ltd as a licence requirement for this medicine and forms part of the Risk Management Plan.

FOR DISPENSARY USE ONLY Warning Labels with Valproate Pregnancy Pictogram for Pharmacy to use with white box dispensing of these products.. For hard copies of this information please contact medical information department on +44 (0)1353 882875 or e-mail [email protected]

Educational material for Healthcare Professionals on important safety information associated with Valproate use. For hard copies of this information please contact medical information department on +44 (0)1353 882875 or e-mail [email protected]

Educational material for girls and women of childbearing potential about the Pregnancy Prevention Programme. For hard copies of this information please contact medical information department on +44 (0)1353 882875 or e-mail [email protected]

Educational material for patients on important safety information associated with Valproate use. For hard copies of this information please contact medical information department on +44 (0)1353 882875 or e-mail [email protected]

FOR DISPENSARY USE ONLY Dispensary A4 Poster for Pharmacy with key information about the Pregnancy Prevention Programme. For hard copies of this information please contact medical information department on +44 (0)1353 882875 or e-mail [email protected]

THIS INTERACTIVE FORM IS NOT INTENDED FOR HARD COPY USE Interactive form for use with girls and women of childbearing potential taking this product. It is to be completed with their specialist at least once a year to make sure they know and have understood all the risks related to the use of valproate during pregnancy and the need to avoid becoming pregnant while taking valproate.

THIS INTERACTIVE FORM IS NOT INTENDED FOR HARD COPY USE Interactive form for male patients aged under 55 years to complete with their specialists when starting valproate

Patient Alert Card

IV iron. Essential Prescription and Administration Information to Minimise the Risk of Serious Hypersensitivity Reactions

Intravenous (IV) Iron. Important Information for Patients About the Possible Risk of Serious Allergic Reactions with IV iron (medication given by needle into the vein)